RBC Capital Reiterates Buy Rating on NewAmsterdam Pharma
RBC Capital maintains its buy rating for NewAmsterdam Pharma with a $51 price target, a 50.49% upside from the current price.
Key Points
- RBC Capital reiterated its buy rating on NewAmsterdam Pharma with a $51 price target on June 30, 2026.
- RBC Capital's $51 price target implies 50.49% upside from NewAmsterdam Pharma Company N.V.'s ($NAMS) current $33.89 share price.
- Shares of NAMS on NasdaqGM traded near $33.87 on Tuesday, with a market cap of about $3.89 billion.
- Institutional investors like FMR LLC increased their holdings by 36.7%, ending with 8.77 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
RBC Capital analyst Leonid Timashev reiterated a buy rating on NewAmsterdam Pharma Company N.V. (NasdaqGM: NAMS) on June 30, 2026. The firm set a price target of $51 for the biotechnology company, which focuses on therapies for cardiometabolic diseases.
RBC Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in NewAmsterdam Pharma
Frazier Life Sciences Management held its position steady with 16.94 million shares valued at about $542.4 million. Capital World Investors increased its stake by 1.13 million shares, bringing its total to 11.11 million shares worth approximately $355.6 million, marking an 11.3% increase. RA Capital Management maintained its holdings with 9.55 million shares valued at $305.7 million. FMR LLC significantly boosted its position by 2.35 million shares, a 36.7% increase, resulting in 8.77 million shares valued at $280.6 million.
NewAmsterdam Pharma Company N.V. Stock Up 30.8%
Shares of NewAmsterdam Pharma traded near $33.87 on Tuesday. The company has a market cap of approximately $3.89 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is a low 0.078, indicating minimal volatility. It has a 52-week range between $17.97 and $42.21, with a 50-day moving average of $32.66 and a 200-day moving average of $33.43.
$NAMS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at NewAmsterdam Pharma Company N.V.
Chief Accounting Officer Louise Frederika Kooij was active in recent transactions, selling 40,000 shares at an average price of $30.20 on June 22, 2026, as part of a planned transaction. She also purchased 40,000 shares at $11.28 on the same day. Earlier, on May 26, 2026, Kooij sold 65,000 shares at $35.69 in a planned sale, while also buying 65,000 shares at $10.07.
Analysts Set New Price Targets
On June 30, 2026, RBC Capital maintained its buy rating and set a $51 price target. Guggenheim and Needham also maintained buy ratings earlier in the year, with price targets of $45 and $48, respectively. Overall, the consensus among 14 analysts is a buy, with a mean price target of $49.18.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company headquartered in Naarden, Netherlands. It focuses on developing therapies for cardiometabolic diseases, including Obicetrapib, an oral CETP inhibitor for lowering LDL-C. The company is led by CEO Dr. Michael Harvey Davidson and employs around 100 people.
Bottom Line
RBC Capital's reiterated buy rating and $51 price target underline continued confidence in NewAmsterdam Pharma's potential. While the company's current lack of profitability affects its forward P/E ratio, its focus on innovative therapies keeps it on the radar of investors and analysts alike. Institutional interest remains strong, with significant increases in holdings by funds like FMR LLC.
Get NewAmsterdam Pharma Company N.V. alerts
New 13F filings, insider trades, and analyst moves on $NAMS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.